I follow AUXL in the stock reports. Why? Auxilium Pharmaceuticals, Inc. focuses on developing and marketing specialty biopharmaceutical products to urologists, endocrinologists, orthopedists, and select primary care physicians primarily in the United States. It markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism through its person sales and marketing team. The company has four projects in clinical development, which primarily include AA4500 and AA4010. AA4500, an injectable enzyme, has completed Phase II of development for the treatment of Dupuytren's contracture and is in Phase II of development for the treatment of Peyronie's disease and Frozen Shoulder Syndrome (Adhesive Capsulitis). Auxilium?s transmucosal film product candidate for the treatment of overactive bladder, AA4010, is in Phase I of development. The company also has two pain products using its transmucosal film delivery system in pre-clinical development. In addition, it has rights to six pain products, and products for hormone replacement and urologic disease using its transmucosal film delivery system, and options to all indications using AA4500 for non-topical formulations. Auxilium, under a license and distribution agreement with Ipsen Farmaceutica, B.V., also offers its products in markets of Belgium, Denmark, Finland, Germany, Ireland, Netherlands, Spain, Sweden, and the United Kingdom. The company was founded in 1999 and is headquartered in Malvern, Pennsylvania.

Auxilium Pharmaceuticals Inc.
40 Valley Stream Parkway
Malvern, PA 19355
Phone: 484-321-5900
Fax: 484-321-5999
Web Site: http://www.auxilium.com

I bought some AUXL stock. It rose from $8 to $14 in six months. By being a shareholder I hope to get some insight regarding the results of their AA500 testing and testing results. Stock reports and company profiles may be our best source of information about collengase (AA500).

Yes it's been almost 2 months now since the trials stopped. According to the Motely Fool (a popular stock market information source) the stock is now being heavily "shorted", which means that many investors think it's overvalued and soon to fall.

This doesn't mean the end, problems are to be expected. But Auxilum hasn't said anything publicly about the trials in quite a while now. Has anyone heard anything?

Here is an extract of today's Auxilium press release

-----------------------------------------------------------------------------------
Auxilium expects to:

- resume the phase III clinical trials for AA4500 for the treatment of
Dupuytren's contracture in the fourth quarter of 2007;
-----------------------------------------------------------------------------------

Looks like the disruption of the flow of Collegenase has put approval back another year. Get used to it. This has been gong on now for years. Yes, there is still hope, but don't hold your breath. Meanwhile NA has been shown to do nearly exactly the same thing and Eaton believes that a significant majority of all new patients who need a procedure can use it for the rest of their lives to maintain their disease. I'm having my teeth deep cleaned today and two other times this month. I think maybe I'd rather have NA. :-)

Dear Jim

I not only have the DC, LD, and am developing frozen shoulder...just by the way things are playing out I must say that I am happy to not be a guy...I know where my track record so far would lead me.

Kristine